Healthcare Sector
Market Tracker
15m Chart - Support and Resistance levels are based on the large dark pool & equity prints at the plotted levels. Displays strongest levels above and below the spot price.
Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.
Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.
Represents the largest cumulative premium levels above and below the current spot price. The price in the pink bubble represents the spot price.
Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.
| Expires | Type | Strike | OI | Change | Percent |
|---|---|---|---|---|---|
| 05/15/2026 | CALL | $55.00 | 79 | +79 | |
| 05/15/2026 | CALL | $55.00 | 77 | +77 | |
| 05/15/2026 | CALL | $30.00 | 53 | +53 | |
| 05/15/2026 | CALL | $30.00 | 53 | +53 | |
| 05/15/2026 | CALL | $50.00 | 51 | +51 | |
| 05/15/2026 | CALL | $50.00 | 51 | +51 | |
| 11/20/2026 | PUT | $75.00 | 0 | 0 | |
| 11/20/2026 | PUT | $80.00 | 0 | 0 | |
| 11/20/2026 | PUT | $85.00 | 0 | 0 | |
| 11/20/2026 | PUT | $90.00 | 0 | 0 | |
| 11/20/2026 | PUT | $95.00 | 0 | 0 | |
| 11/20/2026 | PUT | $100.00 | 0 | 0 |
Contracts with largest changes in open interest from the previous trading day to the current/most recent.
| Name | Pct Held | Shares | Total |
|---|---|---|---|
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 2.48% | 701.63k | 17.73M |
| Federated Hermes Kaufmann Small Cap Fund | 2.33% | 658.62k | 16.64M |
| Federated Hermes Kaufmann Fund | 2.06% | 583.08k | 14.73M |
| Vanguard Total Stock Market Index Fund | 1.93% | 544.68k | 13.76M |
| Vanguard Small-Cap Index Fund | 1.60% | 453.13k | 11.45M |
| iShares Russell 2000 ETF | 1.48% | 418.07k | 10.56M |
| Vanguard Small-Cap Growth Index Fund | 0.96% | 271.17k | 6.85M |
| Vanguard Extended Market Index Fund | 0.94% | 265.23k | 6.7M |
| iShares Russell 2000 Value ETF | 0.73% | 207.22k | 5.24M |
| iShares NASDAQ Biotechnology ETF | 0.68% | 190.67k | 4.82M |
| DFA U.S. Targeted Value Portfolio | 0.58% | 163.29k | 4.13M |
| DFA U.S. Small Cap Series | 0.51% | 143.87k | 3.64M |
| Fidelity Small Cap Index Fund | 0.49% | 138.64k | 3.5M |
| Fidelity Select Portfolios - Biotechnology | 0.46% | 129.4k | 3.27M |
| DFA U.S. Micro Cap Series | 0.43% | 122.7k | 3.1M |
| TIAA-CREF Funds-Quant Small Cap Equity Fund | 0.42% | 118.14k | 2.99M |
| Northern Small Cap Value Fund | 0.42% | 117.74k | 2.98M |
| College Retirement Equities Fund-Stock Account | 0.37% | 103.61k | 2.62M |
| Fidelity Extended Market Index Fund | 0.35% | 99.65k | 2.52M |
Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary
01/08 07:00 pm
GlobeNewswire Inc.
Read moreGSK Unit Tesaro Sues AnaptysBio, Threatening Key Cancer Drug Jemperli Royalties
11/21 09:48 am
Benzinga
Read moreAnaptys Initiates Litigation Against Tesaro, a GSK Subsidiary
11/21 04:50 am
GlobeNewswire Inc.
Read more12 Health Care Stocks Moving In Monday's After-Market Session
09/29 05:06 pm
Benzinga
Read morePsoriasis Market Outlook in the 7MM Through 2034: In-Depth Analysis by Psoriasis Type | DelveInsight
04/14 01:00 pm
GlobeNewswire Inc.
Read moreWhy AnaptysBio Was Such a Healthy Stock This Week
08/23 07:26 am
The Motley Fool
Read moreAnaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering
08/14 05:00 am
GlobeNewswire Inc.
Read moreRepligen (RGEN) Soars 4.4%: Is Further Upside Left in the Stock?
06/24 07:33 am
Zacks Investment Research
Read moreThe Analyst Landscape: 7 Takes On AnaptysBio
05/10 05:01 pm
Benzinga
Read moreAnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates
05/09 05:45 pm
Zacks Investment Research
Read moreAnaptys Announces First Quarter 2024 Financial Results and Provides Business Update
05/09 04:15 pm
GlobeNewswire Inc.
Read moreAnaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
05/09 04:10 pm
GlobeNewswire Inc.
Read moreCytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Tops Revenue Estimates
05/08 07:30 pm
Zacks Investment Research
Read moreGuardant (GH) Gears Up for Q1 Earnings: Here's What to Expect
05/07 11:29 am
Zacks Investment Research
Read moreIovance (IOVA) Gears Up for Q1 Earnings: Here's What to Expect
05/06 09:56 am
Zacks Investment Research
Read moreAnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
05/02 10:01 am
Zacks Investment Research
Read moreAnaptysBio (ANAB) Soars 14.3%: Is Further Upside Left in the Stock?
05/01 04:51 am
Zacks Investment Research
Read moreWhy AnaptysBio Stock Zoomed Nearly 8% Higher This Week
04/12 07:00 pm
The Motley Fool
Read moreEnliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday
04/11 10:01 am
Benzinga
Read moreWhy You Shouldn't Bet Against AnaptysBio (ANAB) Stock.
04/09 02:40 pm
Zacks Investment Research
Read moreUnveiling 4 Analyst Insights On AnaptysBio
04/01 03:01 pm
Benzinga
Read moreWhat Makes AnaptysBio, Inc. (ANAB) a New Buy Stock
03/14 12:00 pm
Zacks Investment Research
Read moreWall Street Analysts Believe AnaptysBio, Inc. (ANAB) Could Rally 69.62%: Here's is How to Trade
03/14 09:55 am
Zacks Investment Research
Read moreIs ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?
03/14 09:40 am
Zacks Investment Research
Read moreSkin Disease-Focused AnaptysBio Earns Analyst Upgrade On Positive Outlook For Clinical Triggers
03/12 02:48 pm
Benzinga
Read moreAnaptysBio, Inc. (ANAB) Reports Q4 Loss, Tops Revenue Estimates
03/11 05:30 pm
Zacks Investment Research
Read moreAnaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
03/11 04:15 pm
GlobeNewswire Inc.
Read moreAnalysts Estimate Lexicon Pharmaceuticals (LXRX) to Report a Decline in Earnings: What to Look Out for
02/29 11:00 am
Zacks Investment Research
Read moreAnaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting
02/29 10:15 am
GlobeNewswire Inc.
Read moreAnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Should You Buy?
02/28 11:00 am
Zacks Investment Research
Read moreStrength Seen in AnaptysBio, Inc. (ANAB): Can Its 5.9% Jump Turn into More Strength?
02/19 06:54 am
Zacks Investment Research
Read moreStrength Seen in Autolus Therapeutics PLC Sponsored ADR (AUTL): Can Its 6.3% Jump Turn into More Strength?
02/12 03:29 am
Zacks Investment Research
Read moreAnaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference
01/31 10:15 am
GlobeNewswire Inc.
Read moreSarepta (SRPT) Rises on Solid Q4 and 2023 Preliminary Results
01/09 11:52 am
Zacks Investment Research
Read moreCorcept (CORT) Stock Rises on Upbeat Revenue Guidance for 2024
01/09 11:48 am
Zacks Investment Research
Read moreDoes AnaptysBio, Inc. (ANAB) Have the Potential to Rally 69.36% as Wall Street Analysts Expect?
12/07 10:55 am
Zacks Investment Research
Read moreAnaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals
11/27 05:15 pm
GlobeNewswire Inc.
Read moreAtara Biotherapeutics (ATRA) Slumps 57% in a Month: Here's Why
11/24 01:29 pm
Zacks Investment Research
Read moreEntrada (TRDA) Down on FDA Maintaining Clinical Hold on DMD Drug
11/23 12:47 pm
Zacks Investment Research
Read moreMorphoSys (MOR) Down 22% on Mixed Data From Myelofibrosis Study
11/22 02:48 pm
Zacks Investment Research
Read moreGain Therapeutics (GANX) Down 25% on Issue of New Common Stock
11/22 12:58 pm
Zacks Investment Research
Read moreAgios (AGIO) Meets Clinical Proof-of-Concept in Anemia Treatment
11/21 11:56 am
Zacks Investment Research
Read moreKaruna (KRTX) Posts Upbeat Safety Data on Schizophrenia Drug
11/17 12:32 pm
Zacks Investment Research
Read moreMerck (MRK) Gets FDA Nod for Keytruda Expansion in Gastric Cancer
11/17 12:29 pm
Zacks Investment Research
Read moreDown -24.46% in 4 Weeks, Here's Why AnaptysBio, Inc. (ANAB) Looks Ripe for a Turnaround
11/14 10:35 am
Zacks Investment Research
Read moreAnaptys Named a BioSpace 2024 Best Places to Work Winner
11/07 05:15 pm
GlobeNewswire Inc.
Read moreAnaptys Announces Third Quarter 2023 Financial Results and Provides Business Update
11/02 04:15 pm
GlobeNewswire Inc.
Read moreAnaptys Announces Participation in November Investor Conferences
11/01 09:15 am
GlobeNewswire Inc.
Read moreAnaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress
10/11 09:15 am
GlobeNewswire Inc.
Read more